In the early 1960s, Norwegian physician Kåre Berg, M.D., was trying to identify new blood types when he accidentally ...

Now, although the funding environment looks different from the pandemic-era biotech bubble, conditions are ripening for the return of the IPO as a viable exit for private drugmakers, according to a ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

The news is the latest example of the biotech industry's struggles in the Bay Area.

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

Integrated consulting approach streamlines pathway from concept to commercialization NEW YORK, NY, UNITED STATES, April ...

Biotech executives, investors, and R&D leaders all face the same burning question in 2026: How do we scale breakthroughs from ...

Discover what were the top biotech deals that were signed in March 2026. From small molecules to antibodies, M&A activity was high.